American Heart Journal
Volume 158, Issue 5 , Pages 822-828.e3 , November 2009

Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures

  • Warren Laskey, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, University of New Mexico School of Medicine, Albuquerque, NM
    • Corresponding Author InformationReprint requests: Warren K. Laskey, MD, Division of Cardiology, Department of Medicine, MSC10-5550, 1 University of New Mexico, Albuquerque, NM 87131.
    • ,
  • Peter Aspelin, MD

      Affiliations

    • Division of Radiology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Charles Davidson, MD

      Affiliations

    • Department of Medicine, Division of Cardiology, Northwestern University School of Medicine, Chicago, IL
    • ,
  • Michael Rudnick, MD

      Affiliations

    • Division of Nephrology, University of Pennsylvania School of Medicine, Philadelphia, PA
    • ,
  • Pierre Aubry, MD

      Affiliations

    • Department of Cardiology, Centre Hospitalier Universitaire Bichat, Paris, France
    • ,
  • Sreenivas Kumar, MD

      Affiliations

    • CARE Hospital, Andhra, India
    • ,
  • Frank Gietzen, MD

      Affiliations

    • Herz-und Gefass-Klinik Gmbh, Saale, Germany
    • ,
  • Marcus Wiemer, MD

      Affiliations

    • Herz-und Diabeteszentrum Nordhein-Westfalen, Kardiologishe Klinik, Bad Oyenhausen, Germany
    • ,
  • on behalf of the DXV405 Study Group

Received 17 May 2009 ,Accepted 15 August 2009.

References 

  1. Singri N, Ahya SN, Levin ML. Acute renal failure. JAMA. 2003;289:747–751
  2. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430
  3. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11:177–182
  4. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention; incidence, risk factors and relationship to mortality. Am J Med. 1997;103:368–375
  5. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399
  6. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515–1519
  7. Cochran ST, Wong WS, Doe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983;141:1027–1033
  8. Hou SH, Bashinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983;74:243–248
  9. Shusterman N, Strom BL, Murray TG, et al. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med. 1987;83:65–71
  10. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930–936
  11. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275:1489–1494
  12. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–2264
  13. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–1548
  14. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769–2775
  15. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006;98(Suppl):27K–36K
  16. Becker CR, Davidson C, Lameire N, et al. High-risk situations and procedures. Am J Cardiol. 2006;98(Suppl):37K–41K
  17. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(Suppl):59K–77K
  18. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy. A Clinical and evidence-based approach. Circulation. 2006;113:1799–1806
  19. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171–178
  20. Schweiger MJ, Chambers CE, Davidson CJ, et al. Prevention of contrast-induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv. 2007;69:135–140
  21. Morcos SK, Thomsen HS, Webb JA. Contrast-media–induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9:1602–1613
  22. Deray G, Bellin MF, Boulechfar H, et al. Nephrotoxicity of contrast media in high-risk patients with renal insufficiency: comparison of low-and high-osmolar contrast agents. Am J Nephrol. 1991;11:309–312
  23. Campbell DR, Flemming BK, Mason WF, et al. A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol J. 1990;41:133–137
  24. Nikonoff T, Skau T, Berglund J, et al. Effects of femoral arteriography and low osmolar contrast agents on renal function. Acta Radiol. 1993;34:88–91
  25. Sharma S, Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv. 2005;65:386–393
  26. McCullough PA, Bertrand ME, Briner JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low osmolar contrast media. J Am Coll Cardiol. 2006;48:692–699
  27. Rudnick MR, Davidson C, Laskey W, et al. for the VALOR Trial Investigators Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) trial. Am Heart J. 2008;156:776–782
  28. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–499
  29. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999;72:701–703
  30. Hardiek K, Katholi RE, Ogden RN. Double-blind, randomized comparison of iopamidol-370 and iodixanol-320: renal response in diabetic subjects RSNA 2003; 3.12.2003. p.541.
  31. Oldemayer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146:E23
  32. Shyu KG, Cheng J, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383–1388
  33. Taliercio CP, Vliestra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing coronary angiography. J Am Coll Cardiol. 1991;17:384–390
  34. Heinrich MC, Haberle L, Muller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009;250:68–86
  35. Rudnick MR, Goldfarb S, Wexler L, et al. for the Iohexol Cooperative Study Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254–261
  36. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac angiography in renally impaired patients (CARE) study. Circulation. 2007;115:3189–3196
  37. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography (the RECOVER study). J Am Coll Cardiol. 2006;48:924–930
  38. Nie B, Cheng WJ, Li YF, et al. A prospective, double-blind, randomized, controlled trial of the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Cathet Cardiovasc Int. 2008;72:958–965
  39. Marenzi G, Assanelli E, Marana I, et al. N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
  40. Briguori C, Airoldi F, D'Andrea D, et al. A. Renal insufficiency following contrast media administration (REMEDIAL). Circulation. 2007;115:1211–1217

 Trial registration at clinicaltrials.gov: NCT00209430.

 WL, PA, CD, MR, and PA have each received honoraria or research grant support from GE Healthcare, Ltd, Princeton, NJ.

PII: S0002-8703(09)00643-7

doi: 10.1016/j.ahj.2009.08.016

American Heart Journal
Volume 158, Issue 5 , Pages 822-828.e3 , November 2009

Article Tools

* Image Usage & Resolution